Jazz Pharma Buying Actio In Up To $1.32B Epilepsy Push
Dublin-based Jazz Pharmaceuticals PLC said Monday it will pay up to $1.32 billion for privately held Actio Biosciences, with Hogan Lovells Cadwalader advising Jazz and Cooley LLP guiding Actio. ...To view the full article, register now.
Already a subscriber? Click here to view full article